Robert Morlock
Robert Morlock has a total of 87 co-authors. Here are the top co-authors by number of shared publications:
Amy Morlock
Acumen Health Research Institute Ann Arbor Michigan
4 shared publications- Brian E. Lacy
Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, USA
2 shared publications Ceciel Rooker
2 shared publicationsDouglas C. Taylor
2 shared publications- John H. Powers
Department of Medicine, School of Medicine, George Washington University, Washington, DC 20052, USA
2 shared publications - Nicolaas J. Reus
Department of Ophthalmology, Amphia Hospital, Breda, Netherlands
2 shared publications
Latest Publications
- Open Access
- 1 October 2026
- Published by Becaris Publishing Limited in Journal of Comparative Effectiveness Research
- Vol. 15 (10)
US population-level model of clinical impact of lorlatinib treatment on ALK+ metastatic non-small cell lung cancer outcomes
Aim: Lorlatinib and alectinib are next-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) approved for the treatment of ALK-positive (ALK+) advanced/metastatic non-small cell lung cancer (NSCLC) after demonstrating superior efficacy over crizotinib (first-generation ALK TKI) in the CROWN and ALEX trials, respectively. This analysis estimated the US population-level clinical impact of first-line (1L) lorlatinib versus alectinib treatment for ALK+ advanced/metastatic NSCLC. Materials & methods: We developed a decision-analytic model comparing lorlatinib versus alectinib use in 1L. We used a three-state partitioned survival model (pre-progression, post-progression and death) and tracked incidence of brain metastases (BMs). Lorlatinib-eligible population estimates were derived from published literature and market forecasts; treatment effectiveness for lorlatinib was derived from CROWN; alectinib comparative effectiveness was informed using a match-adjusted indirect comparison (CROWN vs ALEX). We assumed lorlatinib uptake of 38% in the base case; selected scenarios included different survival extrapolations, assuming 100% lorlatinib uptake and applying risk of BM post-discontinuation. Results: We estimated that 3096 patients in the US would be eligible for lorlatinib. Compared with 1L alectinib use only, our model projected that 1L lorlatinib treatment results in 1620–5170 and 1590–4880 more life-years and quality-adjusted life-years, respectively, over a 20-year time horizon across scenarios. Per-patient incidence of BM ranged from 0.14–0.18 and 0.21–0.40 for lorlatinib and alectinib, respectively, resulting in 68–256 fewer BMs. Separately, for every 5–15 patients treated with 1L lorlatinib instead of 1L alectinib, one BM would be avoided. Conclusion: This analysis projected that 1L lorlatinib treatment in the US could result in more LYs and quality-adjusted life-years and fewer BMs versus 1L alectinib in ALK+ advanced/metastatic NSCLC.
- 1 October 2026
- Published by Becaris Publishing Limited in Journal of Comparative Effectiveness Research
- Vol. 15 (10)
Open AccessUS population-level model of clinical impact of lorlatinib treatment on ALK+ metastatic non-small cell lung cancer outcomes
Aim: Lorlatinib and alectinib are next-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) approved for the treatment of ALK-positive (ALK+) advanced/metastatic non-small cell lung cancer (NSCLC) after demonstrating superior efficacy over crizotinib (first-generation ALK TKI) in the CROWN and ALEX trials, respectively. This analysis estimated the US population-level clinical impact of first-line (1L) lorlatinib versus alectinib treatment for ALK+ advanced/metastatic NSCLC. Materials & methods: We developed a decision-analytic model comparing lorlatinib versus alectinib use in 1L. We used a three-state partitioned survival model (pre-progression, post-progression and death) and tracked incidence of brain metastases (BMs). Lorlatinib-eligible population estimates were derived from published literature and market forecasts; treatment effectiveness for lorlatinib was derived from CROWN; alectinib comparative effectiveness was informed using a match-adjusted indirect comparison (CROWN vs ALEX). We assumed lorlatinib uptake of 38% in the base case; selected scenarios included different survival extrapolations, assuming 100% lorlatinib uptake and applying risk of BM post-discontinuation. Results: We estimated that 3096 patients in the US would be eligible for lorlatinib. Compared with 1L alectinib use only, our model projected that 1L lorlatinib treatment results in 1620–5170 and 1590–4880 more life-years and quality-adjusted life-years, respectively, over a 20-year time horizon across scenarios. Per-patient incidence of BM ranged from 0.14–0.18 and 0.21–0.40 for lorlatinib and alectinib, respectively, resulting in 68–256 fewer BMs. Separately, for every 5–15 patients treated with 1L lorlatinib instead of 1L alectinib, one BM would be avoided. Conclusion: This analysis projected that 1L lorlatinib treatment in the US could result in more LYs and quality-adjusted life-years and fewer BMs versus 1L alectinib in ALK+ advanced/metastatic NSCLC.
- Open Access
- 29 September 2026
- Published by Springer Nature in Journal of Patient-Reported Outcomes
Development and validation of the global spectacle independence questionnaire: a brief patient-reported outcome measure with U.S. population norms
Background: To develop and provide initial validation evidence for the Global Spectacle Independence Questionnaire (GSIQ), a patient-reported outcome measure of spectacle independence (SI), and to provide U.S. national norms of SI. Methods: Instrument development followed U.S. Food and Drug Administration and International Society for Pharmacoeconomics and Outcomes Research guidance. Concept elicitation and cognitive debriefing interviews were conducted in the U.S. ( N = 36). An online survey ( N = 960) representative of the U.S. adult population collected psychometric data to assess reliability and validity relative to the National Eye Institute Refractive Error Quality of Life Instrument-42 (NEI-RQL). The primary endpoint, GSIQ-DC, is a dichotomous classification (DC) of SI defined as responding “None of the time” to all three core items (need for vision correction, wearing vision correction, and straining/squinting without correction) during the past 7 days. Results: Qualitative interviews identified concepts of spectacle independence and achieved concept saturation. The final GSIQ consists of three core items (plus one optional digital-device item). Exploratory factor analysis supported unidimensionality (60.7% variance explained). Internal consistency was strong (Cronbach’s α = 0.82); test-retest reliability was excellent (intraclass correlation coefficient = 0.87). Convergent validity with theoretically related NEI-RQL subscales was moderate to strong; known-groups analysis and logistic regression further supported validity. In the weighted U.S. normative sample, 18.8% of adults were classified as fully spectacle independent. Conclusions: The GSIQ is a concise, reliable patient-reported outcome measure with evidence of validity. Its dichotomous primary endpoint provides a standardized, patient-centered measure of complete spectacle independence for evaluating vision correction interventions across clinical research settings.
- 29 September 2026
- Published by Springer Nature in Journal of Patient-Reported Outcomes
Open AccessDevelopment and validation of the global spectacle independence questionnaire: a brief patient-reported outcome measure with U.S. population norms
Background: To develop and provide initial validation evidence for the Global Spectacle Independence Questionnaire (GSIQ), a patient-reported outcome measure of spectacle independence (SI), and to provide U.S. national norms of SI. Methods: Instrument development followed U.S. Food and Drug Administration and International Society for Pharmacoeconomics and Outcomes Research guidance. Concept elicitation and cognitive debriefing interviews were conducted in the U.S. ( N = 36). An online survey ( N = 960) representative of the U.S. adult population collected psychometric data to assess reliability and validity relative to the National Eye Institute Refractive Error Quality of Life Instrument-42 (NEI-RQL). The primary endpoint, GSIQ-DC, is a dichotomous classification (DC) of SI defined as responding “None of the time” to all three core items (need for vision correction, wearing vision correction, and straining/squinting without correction) during the past 7 days. Results: Qualitative interviews identified concepts of spectacle independence and achieved concept saturation. The final GSIQ consists of three core items (plus one optional digital-device item). Exploratory factor analysis supported unidimensionality (60.7% variance explained). Internal consistency was strong (Cronbach’s α = 0.82); test-retest reliability was excellent (intraclass correlation coefficient = 0.87). Convergent validity with theoretically related NEI-RQL subscales was moderate to strong; known-groups analysis and logistic regression further supported validity. In the weighted U.S. normative sample, 18.8% of adults were classified as fully spectacle independent. Conclusions: The GSIQ is a concise, reliable patient-reported outcome measure with evidence of validity. Its dichotomous primary endpoint provides a standardized, patient-centered measure of complete spectacle independence for evaluating vision correction interventions across clinical research settings.
- 1 April 2026
- Published by Wolters Kluwer Health in Journal of Cataract & Refractive Surgery
- Vol. 52 (4) , 354-360
Evaluation of spectacle independence with the Dutch Patient-Reported Spectacle Independence Questionnaire
Purpose: To evaluate spectacle independence in healthy individuals and cataract patients with different types of intraocular lenses (IOLs) and refractive targets using a Dutch translation of The Patient-Reported Spectacle Independence Questionnaire (PRSIQ). The PRSIQ is a patient-reported outcome measure that assesses patient need for, wearing of, and functioning without spectacles for distance, intermediate, and near vision. Setting: Amphia Hospital, Breda, the Netherlands. Design: Prospective, observational, cross-sectional, single-center study. Methods: The English questionnaire was translated to Dutch following the ISPOR guidelines. 361 participants across various groups were included: healthy individuals aged younger than and older than 50 years and cataract patients with bilateral implantation of monofocal, enhanced monofocal, toric monofocal, monofocal with a myopic target, extended depth-of-focus (EDOF), or trifocal IOLs. Results: Dichotomous scoring showed significantly different rates of complete spectacle independence: 28 of 49 (57%) for trifocals, 8 of 47 (17%) for EDOFs, 2 of 44 (5%) for monofocals, 1 of 50 (2%) for enhanced monofocals, 0 of 25 (0%) for toric monofocals, 1 of 46 (2%) for myopic targets, and 10 of 50 (20%) and 1 of 50 (2%) for healthy participants younger than and older than 50 years. Participants with minimal refractive errors reported complete spectacle independence in 20 of 28 (71%) with trifocals and 5 of 21 (24%) with EDOF IOLs. Rasch analysis showed that the questionnaire was multidimensional and thus failed to support interval scaling. Conclusions: The Dutch PRSIQ-NL demonstrated significant differences in self-reported complete spectacle independence across IOL types and refractive targets using dichotomous scoring. Rasch analysis showed PRSIQ-NL cannot be used for interval-scaled measurements. The PRSIQ-NL is valuable for clinical and research applications to evaluate spectacle independence using dichotomous scoring.
- 1 April 2026
- Published by Wolters Kluwer Health in Journal of Cataract & Refractive Surgery
- Vol. 52 (4) , 354-360
Evaluation of spectacle independence with the Dutch Patient-Reported Spectacle Independence Questionnaire
Purpose: To evaluate spectacle independence in healthy individuals and cataract patients with different types of intraocular lenses (IOLs) and refractive targets using a Dutch translation of The Patient-Reported Spectacle Independence Questionnaire (PRSIQ). The PRSIQ is a patient-reported outcome measure that assesses patient need for, wearing of, and functioning without spectacles for distance, intermediate, and near vision. Setting: Amphia Hospital, Breda, the Netherlands. Design: Prospective, observational, cross-sectional, single-center study. Methods: The English questionnaire was translated to Dutch following the ISPOR guidelines. 361 participants across various groups were included: healthy individuals aged younger than and older than 50 years and cataract patients with bilateral implantation of monofocal, enhanced monofocal, toric monofocal, monofocal with a myopic target, extended depth-of-focus (EDOF), or trifocal IOLs. Results: Dichotomous scoring showed significantly different rates of complete spectacle independence: 28 of 49 (57%) for trifocals, 8 of 47 (17%) for EDOFs, 2 of 44 (5%) for monofocals, 1 of 50 (2%) for enhanced monofocals, 0 of 25 (0%) for toric monofocals, 1 of 46 (2%) for myopic targets, and 10 of 50 (20%) and 1 of 50 (2%) for healthy participants younger than and older than 50 years. Participants with minimal refractive errors reported complete spectacle independence in 20 of 28 (71%) with trifocals and 5 of 21 (24%) with EDOF IOLs. Rasch analysis showed that the questionnaire was multidimensional and thus failed to support interval scaling. Conclusions: The Dutch PRSIQ-NL demonstrated significant differences in self-reported complete spectacle independence across IOL types and refractive targets using dichotomous scoring. Rasch analysis showed PRSIQ-NL cannot be used for interval-scaled measurements. The PRSIQ-NL is valuable for clinical and research applications to evaluate spectacle independence using dichotomous scoring.
- Open Access
- 26 December 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (1)
Physician Antibiotic Prescribing Preferences in Community Acquired Pneumonia and Complicated Urinary Tract Infections: A National Discrete Choice Experiment
Background: Physicians prescribing antibiotics for common infections must weigh trade-offs across drug attributes such as efficacy, dosing, side effects, and resistance. Understanding these priorities can help inform drug development, regulatory decisions, and insurance coverage determinations. Methods: We conducted a discrete choice experiment between June 5 and 9 July 2024, among a national sample of US physicians who prescribed antibiotics for community-acquired pneumonia (CAP) or complicated urinary tract infections (UTIs) in the past year. Respondents evaluated paired hypothetical antibiotics varying by 5 attributes: time to symptom improvement, dosing frequency, risk of nonserious and serious side effects, and risk of future resistance to the patient. Preference weights and relative importance scores were estimated using conditional logistic models. Subgroup analyses were conducted by disease, care setting, and specialty. Results: Of 880 enrolled physicians, 756 (86%) completed the survey. Respondents had a mean age of 51.5 years; 60% were male, and most practiced general internal medicine (64%) or infectious disease (15%). The most influential attributes overall were symptom improvement (relative importance score: 28%) and dosing convenience (relative importance score: 27%). In inpatient settings, physicians prioritized symptom improvement (relative importance score: 33%), while outpatient physicians prioritized dosing frequency (relative importance score: 31%). Risk of future antibiotic resistance to the patient was consistently the least influential attribute (relative importance score: 7%–13%) across disease-types and clinical settings. Conclusions: In this national survey study, physicians prioritized rapid symptom relief and dosing convenience over other drug attributes when prescribing antibiotics for CAP and UTIs. Understanding physician priorities can help inform stewardship strategies and clinician-facing decision support, and encourage regulators and sponsors to prioritize clinically meaningful trial endpoints.
- 26 December 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (1)
Open AccessPhysician Antibiotic Prescribing Preferences in Community Acquired Pneumonia and Complicated Urinary Tract Infections: A National Discrete Choice Experiment
Background: Physicians prescribing antibiotics for common infections must weigh trade-offs across drug attributes such as efficacy, dosing, side effects, and resistance. Understanding these priorities can help inform drug development, regulatory decisions, and insurance coverage determinations. Methods: We conducted a discrete choice experiment between June 5 and 9 July 2024, among a national sample of US physicians who prescribed antibiotics for community-acquired pneumonia (CAP) or complicated urinary tract infections (UTIs) in the past year. Respondents evaluated paired hypothetical antibiotics varying by 5 attributes: time to symptom improvement, dosing frequency, risk of nonserious and serious side effects, and risk of future resistance to the patient. Preference weights and relative importance scores were estimated using conditional logistic models. Subgroup analyses were conducted by disease, care setting, and specialty. Results: Of 880 enrolled physicians, 756 (86%) completed the survey. Respondents had a mean age of 51.5 years; 60% were male, and most practiced general internal medicine (64%) or infectious disease (15%). The most influential attributes overall were symptom improvement (relative importance score: 28%) and dosing convenience (relative importance score: 27%). In inpatient settings, physicians prioritized symptom improvement (relative importance score: 33%), while outpatient physicians prioritized dosing frequency (relative importance score: 31%). Risk of future antibiotic resistance to the patient was consistently the least influential attribute (relative importance score: 7%–13%) across disease-types and clinical settings. Conclusions: In this national survey study, physicians prioritized rapid symptom relief and dosing convenience over other drug attributes when prescribing antibiotics for CAP and UTIs. Understanding physician priorities can help inform stewardship strategies and clinician-facing decision support, and encourage regulators and sponsors to prioritize clinically meaningful trial endpoints.
- Open Access
- 13 November 2025
- Published by Oxford University Press (OUP) in Health Affairs Scholar
- Vol. 3 (12) , qxaf219
Availability of consent forms in ClinicalTrials.gov for industry sponsored trials
- 13 November 2025
- Published by Oxford University Press (OUP) in Health Affairs Scholar
- Vol. 3 (12) , qxaf219
Open AccessAvailability of consent forms in ClinicalTrials.gov for industry sponsored trials
- Open Access
- 5 November 2024
- Published by Wiley in ACR Open Rheumatology
- Vol. 7 (1)
Gout Flare Burden in the United States: A Multiyear Cross‐Sectional Survey Study
Objective: The objective of this study was to assess the burden of gout flares and examine associated patient characteristics and outcomes in a sample of US adults.Methods: Data were collected via an online survey of US adults ≥18 years using a random stratified sampling framework. Participants with gout completed questions about treatments, serum urate (SU) levels, severity, satisfaction with control, and gout flares. All participants completed the Veterans RAND 12‐Item Health Survey, the Generalized Anxiety Disorder 7‐Item Scale, and the Patient Health Questionnaire 9‐Item Scale. Data were summarized using descriptive statistics. Multivariable‐adjusted logistic regression analyses examined factors predictive of reporting gout flares to a physician.Results: A total of 933 participants met the study criteria for having gout. Those with gout tended to be older (58.3 [SD 13.3] years vs 45.4 [SD 16.1] years; P < 0.001), male (76.3% vs 46.9%; P < 0.001), White (80.5% vs 76.8%; P = 0.01), and married or living with their partner (58.9% vs 52.8%; P < 0.001) compared with those without gout (n = 30,146). The total gout flare burden for those with gout was 6.6 gout flares per year. Nearly 72% of gout flares were either not reported to physicians or pretreated or prevented. Characteristics of those who were less likely to report gout flares included being younger, being less educated, having a lower Charlson Comorbidity Index score, not being diagnosed with gout by their doctor, and not taking a urate‐lowering therapy.Conclusion: This study confirmed that gout flares are common in US adults with gout and found that gout flares are underreported. Reliance on clinical documentation of physician‐reported gout flares is insufficient to assess the true patient burden of gout.
- 5 November 2024
- Published by Wiley in ACR Open Rheumatology
- Vol. 7 (1)
Open AccessGout Flare Burden in the United States: A Multiyear Cross‐Sectional Survey Study
Objective: The objective of this study was to assess the burden of gout flares and examine associated patient characteristics and outcomes in a sample of US adults.Methods: Data were collected via an online survey of US adults ≥18 years using a random stratified sampling framework. Participants with gout completed questions about treatments, serum urate (SU) levels, severity, satisfaction with control, and gout flares. All participants completed the Veterans RAND 12‐Item Health Survey, the Generalized Anxiety Disorder 7‐Item Scale, and the Patient Health Questionnaire 9‐Item Scale. Data were summarized using descriptive statistics. Multivariable‐adjusted logistic regression analyses examined factors predictive of reporting gout flares to a physician.Results: A total of 933 participants met the study criteria for having gout. Those with gout tended to be older (58.3 [SD 13.3] years vs 45.4 [SD 16.1] years; P < 0.001), male (76.3% vs 46.9%; P < 0.001), White (80.5% vs 76.8%; P = 0.01), and married or living with their partner (58.9% vs 52.8%; P < 0.001) compared with those without gout (n = 30,146). The total gout flare burden for those with gout was 6.6 gout flares per year. Nearly 72% of gout flares were either not reported to physicians or pretreated or prevented. Characteristics of those who were less likely to report gout flares included being younger, being less educated, having a lower Charlson Comorbidity Index score, not being diagnosed with gout by their doctor, and not taking a urate‐lowering therapy.Conclusion: This study confirmed that gout flares are common in US adults with gout and found that gout flares are underreported. Reliance on clinical documentation of physician‐reported gout flares is insufficient to assess the true patient burden of gout.
- Open Access
Development of the treatment preference in myelodysplasia questionnaire for clinicians, carers, and patients
This study reports the development activities for the Treatment Preference Myelodysplasia Questionnaires (TPMQ) for clinicians (mTPMQ), carers (cTPMQ), and patients (pTPMQ). These tools are intended to evaluate treatment preferences for patients with myelodysplastic syndromes (MDS). This was a non‐interventional, cross‐sectional qualitative interview study consisting of interviews with clinicians, patients, and those caring for patients with MDS. All participants were located in Australia and data were collected from qualitative mixed‐method interviews composed of concept elicitation and cognitive debriefing related to initial drafts of the questionnaires. Fifteen individuals participated in interviews (five from each group). Based on the concept elicitation portion of interviews, concepts of importance were classified and reasons for treatment preference were documented. From cognitive debriefing, the questionnaires were generally deemed to be clear and easy to understand. Participant input from both concept elicitation and cognitive debriefing portions was used to revise initial drafts of the questionnaires. The mTPMQ, cTPMQ, and pTPMQ were developed with direct input from clinicians, patients, and caregivers to assess the key concepts of interest related to the preference for the treatment of MDS and are ready to be used and evaluated further in clinical trials.
Open AccessDevelopment of the treatment preference in myelodysplasia questionnaire for clinicians, carers, and patients
This study reports the development activities for the Treatment Preference Myelodysplasia Questionnaires (TPMQ) for clinicians (mTPMQ), carers (cTPMQ), and patients (pTPMQ). These tools are intended to evaluate treatment preferences for patients with myelodysplastic syndromes (MDS). This was a non‐interventional, cross‐sectional qualitative interview study consisting of interviews with clinicians, patients, and those caring for patients with MDS. All participants were located in Australia and data were collected from qualitative mixed‐method interviews composed of concept elicitation and cognitive debriefing related to initial drafts of the questionnaires. Fifteen individuals participated in interviews (five from each group). Based on the concept elicitation portion of interviews, concepts of importance were classified and reasons for treatment preference were documented. From cognitive debriefing, the questionnaires were generally deemed to be clear and easy to understand. Participant input from both concept elicitation and cognitive debriefing portions was used to revise initial drafts of the questionnaires. The mTPMQ, cTPMQ, and pTPMQ were developed with direct input from clinicians, patients, and caregivers to assess the key concepts of interest related to the preference for the treatment of MDS and are ready to be used and evaluated further in clinical trials.
- 16 June 2022
- Published by Elsevier in Gastroenterology
- Vol. 162 (7)
Mo1084: UNDIAGNOSED IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) AND CHRONIC IDIOPATHIC CONSTIPATION (CIC): MORE COMMON THAN WE THOUGHT?
- 16 June 2022
- Published by Elsevier in Gastroenterology
- Vol. 162 (7)
Mo1084: UNDIAGNOSED IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) AND CHRONIC IDIOPATHIC CONSTIPATION (CIC): MORE COMMON THAN WE THOUGHT?
- 16 June 2022
- Published by Elsevier in Gastroenterology
- Vol. 162 (7)
Tu1339: CHRONIC IDIOPATHIC CONSTIPATION SUFFERERS AND TREATMENT SATISFACTION: PRESCRIPTION VS. OVER-THE-COUNTER MEDICATIONS
- 16 June 2022
- Published by Elsevier in Gastroenterology
- Vol. 162 (7)
Tu1339: CHRONIC IDIOPATHIC CONSTIPATION SUFFERERS AND TREATMENT SATISFACTION: PRESCRIPTION VS. OVER-THE-COUNTER MEDICATIONS
- 10 April 2022
- Published by Oxford University Press (OUP) in The Journal of Sexual Medicine
- Vol. 19 (6) , 975-982
Sexual Satisfaction Results with the Vaginal pH Modulator from the Phase 3 AMPOWER Study
Background: The novel vaginal pH modulator (VPM; Phexxi) is a non-hormonal, woman-controlled, on-demand, water-based, surfactant-free contraceptive vaginal gel; VPM has also been cleared by the Food and Drug Administration for use as a personal lubricant.Aim: The aim of this study is to report on sexual satisfaction results from the phase 3 AMPOWER study.Methods: AMPOWER was a single-arm, open-label, multicenter study to assess the safety and efficacy of VPM in preventing pregnancy. Women were enrolled who were healthy, age 18-35 years, and sexually active with regular cyclic menses.Outcomes: Women’s satisfaction (including sexual satisfaction) was an exploratory endpoint measured at Baseline and Visits 3-5; sexual satisfaction-related patient reported outcomes (PROs) were assessed via 3 different questions: (i) a question related to the impact on a woman’s sex life; (ii) a question from the Sexual Function Questionnaire (SFQ) related to the frequency of ten sexual problems; and (iii) a question from the Female Sexual Function Index (FSFI) related to lubrication.Results: For sexual satisfaction-related PRO measures with baseline assessments, the majority of women reported the same or improved scores at Visit 5 (ranging from 85.8% to 98.4%). The percentage of women who reported that their sex life was improved and/or maintained was higher in Visit 3, 4, and 5 (95.4%, 95.1%, and 93.6%, respectively) compared to Baseline (87.6%). The mean impact on sex life score significantly improved at Visit 5 compared to Baseline (P < .001). In the SFQ, the mean score significantly improved (P < .005) at Visit 5 vs Baseline in 7 of the 10 variables measured (vaginal dryness, lack of sexual interest and/or desire, vaginal tightness, pain, anxiety, unable to orgasm, and vaginal bleeding or irritation). In women who reported sexual activity in the last 4 weeks, the mean FSFI score also significantly improved from Baseline to Visit 5 (P = .037).Clinical Implications: In this post-hoc analysis of the phase 3 AMPOWER study, the PRO results demonstrate a high level of sexual satisfaction with VPM.Strengths and Limitations: The primary strength of this analysis was the large study size of 1,330 women. Limitations included the non-randomized study design, the post-hoc nature of the analysis, and the fact that sexual satisfaction was an exploratory endpoint.Conclusion: As a non-hormonal, woman-controlled, on-demand, lubricating contraceptive gel, VPM offers women a unique set of benefits with positive impacts on their sexual health.
- 10 April 2022
- Published by Oxford University Press (OUP) in The Journal of Sexual Medicine
- Vol. 19 (6) , 975-982
Sexual Satisfaction Results with the Vaginal pH Modulator from the Phase 3 AMPOWER Study
Background: The novel vaginal pH modulator (VPM; Phexxi) is a non-hormonal, woman-controlled, on-demand, water-based, surfactant-free contraceptive vaginal gel; VPM has also been cleared by the Food and Drug Administration for use as a personal lubricant.Aim: The aim of this study is to report on sexual satisfaction results from the phase 3 AMPOWER study.Methods: AMPOWER was a single-arm, open-label, multicenter study to assess the safety and efficacy of VPM in preventing pregnancy. Women were enrolled who were healthy, age 18-35 years, and sexually active with regular cyclic menses.Outcomes: Women’s satisfaction (including sexual satisfaction) was an exploratory endpoint measured at Baseline and Visits 3-5; sexual satisfaction-related patient reported outcomes (PROs) were assessed via 3 different questions: (i) a question related to the impact on a woman’s sex life; (ii) a question from the Sexual Function Questionnaire (SFQ) related to the frequency of ten sexual problems; and (iii) a question from the Female Sexual Function Index (FSFI) related to lubrication.Results: For sexual satisfaction-related PRO measures with baseline assessments, the majority of women reported the same or improved scores at Visit 5 (ranging from 85.8% to 98.4%). The percentage of women who reported that their sex life was improved and/or maintained was higher in Visit 3, 4, and 5 (95.4%, 95.1%, and 93.6%, respectively) compared to Baseline (87.6%). The mean impact on sex life score significantly improved at Visit 5 compared to Baseline (P < .001). In the SFQ, the mean score significantly improved (P < .005) at Visit 5 vs Baseline in 7 of the 10 variables measured (vaginal dryness, lack of sexual interest and/or desire, vaginal tightness, pain, anxiety, unable to orgasm, and vaginal bleeding or irritation). In women who reported sexual activity in the last 4 weeks, the mean FSFI score also significantly improved from Baseline to Visit 5 (P = .037).Clinical Implications: In this post-hoc analysis of the phase 3 AMPOWER study, the PRO results demonstrate a high level of sexual satisfaction with VPM.Strengths and Limitations: The primary strength of this analysis was the large study size of 1,330 women. Limitations included the non-randomized study design, the post-hoc nature of the analysis, and the fact that sexual satisfaction was an exploratory endpoint.Conclusion: As a non-hormonal, woman-controlled, on-demand, lubricating contraceptive gel, VPM offers women a unique set of benefits with positive impacts on their sexual health.